RenovoRx (RNXT) Competitors $0.90 -0.04 (-4.39%) Closing price 03:56 PM EasternExtended Trading$0.90 0.00 (-0.22%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNXT vs. CTOR, FATE, HURA, CGEN, ACOG, GNLX, IKT, SCLX, CHRS, and CGTXShould you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Citius Oncology (CTOR), Fate Therapeutics (FATE), TuHURA Biosciences (HURA), Compugen (CGEN), Alpha Cognition (ACOG), Genelux (GNLX), Inhibikase Therapeutics (IKT), Scilex (SCLX), Coherus Oncology (CHRS), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry. RenovoRx vs. Its Competitors Citius Oncology Fate Therapeutics TuHURA Biosciences Compugen Alpha Cognition Genelux Inhibikase Therapeutics Scilex Coherus Oncology Cognition Therapeutics Citius Oncology (NASDAQ:CTOR) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends. Which has more volatility & risk, CTOR or RNXT? Citius Oncology has a beta of 3, indicating that its share price is 200% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Which has preferable earnings and valuation, CTOR or RNXT? Citius Oncology has higher earnings, but lower revenue than RenovoRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius OncologyN/AN/AN/AN/AN/ARenovoRx$40K823.71-$8.81M-$0.38-2.37 Do analysts recommend CTOR or RNXT? Citius Oncology presently has a consensus target price of $3.00, indicating a potential upside of 58.73%. RenovoRx has a consensus target price of $7.25, indicating a potential upside of 706.45%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00RenovoRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CTOR or RNXT more profitable? Citius Oncology's return on equity of -51.93% beat RenovoRx's return on equity.Company Net Margins Return on Equity Return on Assets Citius OncologyN/A -51.93% -22.17% RenovoRx N/A -120.68%-89.23% Does the media favor CTOR or RNXT? In the previous week, RenovoRx had 10 more articles in the media than Citius Oncology. MarketBeat recorded 13 mentions for RenovoRx and 3 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.25 beat RenovoRx's score of -0.25 indicating that Citius Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RenovoRx 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in CTOR or RNXT? 70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 4.6% of Citius Oncology shares are owned by insiders. Comparatively, 9.1% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryRenovoRx beats Citius Oncology on 6 of the 11 factors compared between the two stocks. Get RenovoRx News Delivered to You Automatically Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNXT vs. The Competition Export to ExcelMetricRenovoRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.95M$3.06B$5.75B$9.73BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-2.3720.9930.2525.89Price / Sales823.71387.70474.39123.10Price / CashN/A43.2325.7828.79Price / Book4.739.639.426.00Net Income-$8.81M-$54.08M$3.27B$265.29M7 Day Performance-4.36%2.70%2.08%2.59%1 Month Performance-29.21%4.14%3.63%0.98%1 Year Performance-10.97%9.46%30.13%18.75% RenovoRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNXTRenovoRx2.8794 of 5 stars$0.90-4.4%$7.25+706.5%-6.9%$32.95M$40K-2.376Analyst UpgradeGap UpCTORCitius Oncology1.3456 of 5 stars$1.70-2.9%$3.00+76.5%-6.4%$133.23MN/A0.00N/APositive NewsFATEFate Therapeutics3.9875 of 5 stars$1.14-5.0%$3.58+214.3%-70.1%$131.48M$8.47M-0.79550Analyst RevisionHURATuHURA Biosciences1.4755 of 5 stars$3.00-2.9%$12.67+322.2%N/A$131.04MN/A0.00N/ACGENCompugen2.0695 of 5 stars$1.46-5.8%$4.00+174.0%-28.9%$130.29M$27.86M-6.6470Positive NewsACOGAlpha Cognition2.0921 of 5 stars$8.11-4.0%$20.00+146.6%N/A$129.92MN/A-5.07N/AGap DownGNLXGenelux1.6752 of 5 stars$3.43-3.1%$17.75+417.5%+67.3%$129.55M$10K-3.9910News CoverageGap DownIKTInhibikase Therapeutics1.7465 of 5 stars$1.72-0.2%$6.50+278.6%+32.2%$127.65MN/A-0.646News CoverageSCLXScilex2.398 of 5 stars$17.96-7.3%$455.00+2,433.4%-55.8%$125.00M$56.59M-0.6280CHRSCoherus Oncology4.1893 of 5 stars$1.07flat$4.68+337.7%-11.5%$124.37M$266.96M0.69330News CoveragePositive NewsCGTXCognition Therapeutics1.636 of 5 stars$1.67+12.1%$2.83+69.7%+280.8%$122.70MN/A-2.4920Positive NewsGap Up Related Companies and Tools Related Companies CTOR Alternatives FATE Alternatives HURA Alternatives CGEN Alternatives ACOG Alternatives GNLX Alternatives IKT Alternatives SCLX Alternatives CHRS Alternatives CGTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNXT) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access